Refine by
Drug Candidates Suppliers Serving Belarus
80 companies found
Premium
based inFramingham, MASSACHUSETTS (USA)
SCIEX empowers you to solve the most impactful analytical challenges in quantitation and characterization in environmental testing. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field ...
based inBoston, MASSACHUSETTS (USA)
Elucid is harnessing scientific imaging and artificial intelligence to enable quick, accurate, noninvasive diagnoses and precise treatment of cardiovascular disease to enable better patient outcomes. Introducing the first and only non-invasive image ...
Introducing the first and only non-invasive image analysis software that employs CT angiography and patented computer algorithms, based on expert histologic examination of thousands of tissue samples, to objectively quantify the extent and stability ...
based inVancouver, BRITISH COLUMBIA (CANADA)
InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet ...
INM-088 is a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (API) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide ...
based inHeidelberg, GERMANY
Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to ...
Reliable predictions to anticipate risks. Interlinked data to find new targets and design novel drugs. Real-world evidence to evaluate success. These capabilities eliminate the uncertainties that limit drug development but are data-intensive and ...
based inMalvern, PENNSYLVANIA (USA)
Since our founding in 2001, we have had one singular obsession: We strive to give our clients a personalized and collaborative research experience. We are here to help you find the answers you need to develop the best possible drug candidate for ...
Cell-based assays are valuable to probe new drug candidates in the environment of intact cells with physiologic concentrations of substrates, co-factors and ...
based inBoston, MASSACHUSETTS (USA)
At Emulate, we understand that animal studies and reductionist models are limited because they are not based on integrated human biology. By leveraging 21st century technologies, we are able to overcome these limitations with living human in vitro ...
Research mechanisms of neuroinflammation and evaluate the effect of therapeutics in a comprehensive model of the neurovascular ...
based inRochester Hills, MICHIGAN (USA)
Oxford Biomedical Research (OBR) develops, manufactures and markets assay kits, recombinant proteins and antibodies for biomedical research and drug discovery. The company’s primary focus is on the identification and assay of biomarkers for ...
based inDoylestown, PENNSYLVANIA (USA)
Neuropathix, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing a patented product platform of novel molecules from our proprietary socially responsible pain management therapeutics to treat patients with a ...
Neuropathix has focused its science on the research and development of a pipeline of next generation socially responsible pain management ...
based inCharlottesville, VIRGINIA (USA)
LumaCyte is an advanced research and bioanalytics instrumentation company that produces label-free, single cell analysis instrumentation where the use of antibody or genetic labeling is not required for cellular analysis. This revolutionary ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
based inheongju-si, SOUTH KOREA
Curome Biosciences is an innovative R&D company developing therapies to treat mitochondrial dysfunction-related diseases with high unmet medical needs. Curome Biosciences wants to provide solutions for treatment of diseases with high unmet medical ...
based inLondon, UNITED KINGDOM
ReGen (Therapeutics Plc) was formed in February 1998 to develop Colostrinin™, a proline-rich polypeptide complex derived from mammalian colostrum. Colostrinin™ is promoted as having utility as a support for healthy brain ageing and cognition. ...
based inStockholm, SWEDEN
BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of disorders that affect the Central Nervous System. These types of treatments are commonly referred to as disease modifiers. They ...
In Alzheimer’s disease soluble, toxic amyloid beta aggregates are believed to contribute to the neurodegenerative process. Lecanemab, a anti amyloid-beta protofibril antibody, selectively binds to these forms of amyloid beta and eliminates ...
based inParis, FRANCE
The Bioprojet company was founded in 1982 under the impetus of Jeanne-Marie Lecomte and Jean-Charles Schwartz, doctors of pharmacy and sciences. From very different backgrounds, Jeanne-Marie Lecomte made her career in the pharmaceutical industry, ...
based inKaiseraugst, SWITZERLAND
Solvias is a world leader in contract research, development and manufacturing (CRO/CDMO). The industries we serve include pharmaceuticals, biotech, medical devices and cosmetics. We provide integrated analytical services and solutions to the ...
Most drug substances are marketed as crystalline material. Having a crystalline drug candidate is beneficial to development processes and simplifies registration. We offer crystallization screening ...
based inLund, SWEDEN
Our mission is to make it easier to analyze the huge amounts of complex data that are generated by innovations in the fields of genetics and proteomics. We do this by providing powerful visualization-based bioinformatics data analysis tools for ...
Qlucore's clinical diagnostics solutions for multi-omics companion and precision diagnostics include AI-powered, disease-specific machine learning based classifier models and are combined with patient-friendly visualizations in a an easy-to-use ...
based inStockholm, SWEDEN
IBT is a pharmaceutical company with its registered office in Stockholm with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. IBT is currently developing its ...
IBP-9414 for the prevention of necrotizing enterocolitis (NEC) contains the active substance Lactobacillus reuteri, which is a co-evolved human bacterial strain naturally present in breast milk. Lactobacillus reuteri is a live bacteria known to be ...
based inSt-Jean, QUEBEC (CANADA)
We are an innovative pharmaceutical company determined to improve the lige of people with allergy. We have developed our biotechnology with you in mind. How could we turn on sharp insights on allergy and precision medicine into a better life for ...
ANGANY is joining the COVID-19 effort with its promising novel vaccination technology. The unprecedented social and economic upset caused by the pandemic called for social responsibility. ANGANY’s entire team pitched in to join the fight! The ...
based inBerlin, GERMANY
3B Pharmaceuticals GmbH (3BP) is a German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. As a leader in peptide discovery and optimization, 3BP has built a ...
3B Pharmaceuticals have built a drug discovery platform extending from hit identification to early clinical development. Several drug candidates developed through our platform already have been ...